Molecular Partners (NASDAQ:MOLN) Given “Buy” Rating at HC Wainwright

Molecular Partners (NASDAQ:MOLN)‘s stock had its “buy” rating reissued by equities researchers at HC Wainwright in a research note issued to investors on Wednesday,Benzinga reports. They currently have a $13.00 target price on the stock. HC Wainwright’s target price would indicate a potential upside of 189.60% from the stock’s previous close.

Several other equities research analysts also recently weighed in on the stock. Weiss Ratings reissued a “sell (d-)” rating on shares of Molecular Partners in a research report on Friday, April 10th. TD Cowen reissued a “buy” rating on shares of Molecular Partners in a research report on Monday, March 16th. Two investment analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat, Molecular Partners currently has a consensus rating of “Hold” and a consensus target price of $8.38.

Molecular Partners Stock Performance

MOLN opened at $4.49 on Wednesday. The company has a 50-day moving average of $4.52 and a 200-day moving average of $4.28. The company has a market capitalization of $181.24 million, a P/E ratio of -2.26 and a beta of 1.11. Molecular Partners has a 1-year low of $3.36 and a 1-year high of $5.36.

Molecular Partners (NASDAQ:MOLN) last released its earnings results on Thursday, March 12th. The company reported ($0.41) earnings per share for the quarter, missing the consensus estimate of ($0.38) by ($0.03). As a group, sell-side analysts expect that Molecular Partners will post -1.4 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

A hedge fund recently bought a new stake in Molecular Partners stock. SmartHarvest Portfolios LLC purchased a new stake in Molecular Partners AG Sponsored ADR (NASDAQ:MOLN) in the 4th quarter, according to its most recent disclosure with the SEC. The fund purchased 12,311 shares of the company’s stock, valued at approximately $54,000. Institutional investors and hedge funds own 26.55% of the company’s stock.

About Molecular Partners

Molecular Partners AG is a clinical-stage biopharmaceutical company headquartered in Zurich, Switzerland, specializing in the design and development of DARPin® (Designed Ankyrin Repeat Protein) therapies. These small, modular proteins are engineered to bind with high specificity and affinity to disease-relevant targets. The company’s technology platform aims to deliver novel treatments across multiple therapeutic areas by leveraging the unique properties of DARPins, including stability, tissue penetration and multi-specific binding capabilities.

The company’s development pipeline spans infectious diseases, ophthalmology and oncology.